Novel Mechanisms in the Resolution of Post-Surgical Lymphedema - Project Summary
This is a mentored clinical scientist research career development proposal for a junior physician who clinically
treats post-surgical lymphedema and is training to become an independent investigator. Lymphedema results
from lymphatic dysfunction and is characterized by limb enlargement. It is most commonly caused by iatrogenic
injury to the lymphatic system secondary to lymph node excision during the surgical management of cancer (e.g,
breast cancer and melanoma). It is estimated that 5-10 million Americans have lymphedema and 250 million
people are affected worldwide. Morbidity from this chronic condition includes frequent infection, pain, and altered
function. There is currently no cure for this disease. Management includes compression, excisional procedures,
and microsurgical operations vascularized lymph node transfer and lymphovenous bypass (LVB). During LVB,
lymphatics in the affected extremity are anastomosed to veins to bypass the injured area. The operation is
technically challenging, time consuming, and requires advanced equipment.
One-third of patients develop lymphedema following lymphadenectomy. The two thirds of those patients that do
not develop lymphedema have transient postoperative limb swelling which resolves spontaneously. Similarly, a
mouse tail model of lymphedema spontaneously resolves the swelling. We propose the novel hypothesis that
lymphedema-induced spontaneous lymphovenous shunts and lymphangiogenesis lead to the physiological
resolution of lymphedema. We use a murine tail model of lymphedema to test our hypothesis. In Aim 1, we will
determine the mechanism responsible for spontaneous resolution of lymphedema. In addition, this proposal
presents an innovative approach using tissue nanotransfection technology (TNT) to induce lymphovenous
shunts and lymphangiogenesis to improve lymphedema. In Aim 2, we hypothesize that TNT can be used to
topically, focally deliver genetic cargo to improve lymphedema by targeting the C-type lectin like receptor (CLEC-
2), Syk, and Slp76 pathways which keep lymphatics separated from veins. Inducing lymphovenous shunts would
act similarly to LVB currently performed clinically to treat lymphedema.
In summary, these experiments will be high impact in identifying the mechanism of spontaneous lymphatic
resolution. The proposed work adopts a novel approach to managing lymphedema using focal, non-global TNT
directly at the affected area. The candidate is an Assistant Professor at Indiana University who is dedicated to
becoming a physician-scientist. He has obtained a previous Master’s degree in translational and clinical research
at Harvard Medical School. The candidate has multiple pilot and foundation grants, a startup research package,
dedicated laboratory space, and 40% protected time which will be increased to 75% upon obtaining the K08
grant. There is an expert mentorship panel, including the Vice-Chair of Surgery and the candidate’s Division
Chief, who are well funded and experienced in mentoring physician scientists. There is strong institutional
commitment which will facilitate the candidate transition to an independent investigator.